



SUMMARY

Kamari pharma is a clinical stage biotechnology company developing topical and oral drugs for the treatment of dermatological diseases, such as Lichen Simplex Chronicus-itch, and rare severe genetic skin disorders such as keratoderma and others. Kamari's drugs are based on proprietary small molecules that modulate TRPV3, an ion channel who plays a key role in the skin. These novel drugs are intended for helping patients with unmet needs, where efficacious treatments are still unavailable.



SCIENTIFIC APPROACH

TRPV3 is a member of the TRP family highly expressed in skin displaying high permeability to calcium thermo-sensing and nociception. Genetic mutations in the TRPV3 gene, results in Olmsted syndrome, a serious and rare skin disorder. Kamari's leading drug candidates are potent and selective TRPV3 small molecule antagonists demonstrating high efficacy in several in vitro and in vivo models. These molecules demonstrate normalization of skin structure and differentiation, re-formation of the barrier reduction in inflammation and itch. Kamari's novel compounds have the potential of becoming first in-class therapies in the dermatology space for rare skin diseases and itch. Kamari is currently performing Phase Ib clinical trials in patients suffering from Lichen simplex chronicus related itch, in leading medical centers in Germany. Patient recruitment has been completed and results are expected soon. In addition, a Phase Ib in Keratoderma patients is ongoing in Israel and in the UK. An additional trial for Lichen Simplex Chronicus -itch, is expected to be launched shortly in China. Additional Phase Ib studies in patients suffering from other TRPV3 related disorders are in preparation as well.



INDICATIONS

In addition to hereditary Olmsted syndrome, TRPV3 is also involved in the development of genetic skin diseases designated as Keratodermas for which no approved treatments are available, thus providing the opportunity for Kamari to be the first drug on the market and change the lives of many patients around the world. Excessive activation of TRPV3 leads to the release of pruritogenic substances which, induce itch an indication with current market valued at ~12 Billion USD, and is expected to reach 18 Billion USD by 2026.



CORPORATE

Kamari's shareholders are leading Israeli and global healthcare venture capital investors including Pontifax, Arkin, GIBF and Wille Finance. Kamari's intellectual property includes approved patents that cover composition of matter claims for all its compounds and their clinical applications. Kamari Pharma is situated in the Weizmann Science park in Israel.

TEAM

Kamari is led by an experienced and professional management team, with extensive experience in dermatological and rare disease drug development. The team includes Liora Braiman, PhD, Chief Scientific Officer, who has vast experience in dermatology drug development, Asaf Yarkoni, CPA, CFO, and Dayana Michel, MD, VP of Medical development. David Aviezer, Ph.D.,MBA, serves as Kamari's Executive Chairman. David was previously CEO of Protalix Biotherapeutics, who led it to FDA drug approval and listing on the New York Stock Exchange.

The Company is supported by an international team of advisors, including medical and academic key opinion leaders in the field of dermatology, keratodermas and itch.

© 2023 KAMARI PHARMA